Actively Recruiting
Monitoring of Immunity Markers in Intensive Care Patients and Link with Recurrence and Relapse of Ventilator-associated Pneumonia
Led by Centre Hospitalier Intercommunal Aix-Pertuis · Updated on 2024-09-23
40
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
This research investigates the link between ventilator-associated pneumonia (VAP) recurrence and postaggressive immunoparalysis in patients admitted to the Intensive Care Unit (ICU). It aims to evaluate how immune system markers, especially HLA-DR levels, relate to infection relapse, severity of shock, viral reactivation, and patient survival. The study explores whether monitoring immunity can identify patients at higher risk despite proper antibiotic treatment. Participants will have blood collected for HLA-DR dosage at enrollment and weekly thereafter. The study does not involve a treatment intervention but focuses on monitoring immune function over time in ICU patients under mechanical ventilation with infectious pneumonia. This observational design helps assess the relationship between immunoparalysis depth, infection recurrence, and clinical outcomes. During the study, participants undergo regular blood tests to assess immunity and monitor infection status. Researchers will track VAP recurrence, viral reactivation, and immunoparalysis persistence from hospital admission until discharge or death. The primary outcome is VAP relapse occurrence, with secondary measures including immune function depth and infection associations. Participation continues throughout hospitalization, with data collected up to 100 months if applicable.
CONDITIONS
Brief Title
Immunity Markers in Intensive Care Patients and Ventilator-associated Pneumonia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient over 18 years old
- Patient admitted in the Intensive Care Unit of the CHIAP
- Patient under mechanical ventilation
- Patient with infectious pneumonia
- Informed Consent Form (ICF) obtained from the patient or emergency ICF obtained from close relatives
- Patient beneficiary of French social security, whatever the regime
You will not qualify if you...
- Patient under 18 years old
- Patient with severe neutropenia (neutrophils < 0.5 G/L)
- Patient under immunosuppressive treatment
- Use of corticosteroids (intravenous or oral) prior to ICU admission
- Use of therapeutic antibodies
- Onco-hematological disease (e.g. lymphoma, leukemia...) under treatment or treated in the 5 years prior to inclusion
- End of chemotherapy 6 months prior to inclusion
- Patients with innate or acquired immune deficiency (e.g., severe combined immunodeficiency, HIV or AIDS, at any stage)
- Patients with a decision to limit or discontinue active therapies, at the time of inclusion
- Patients with an estimated ICU stay of less than 48 hours
- Participation in an interventional study
- Patient deprived of their liberty
- Patient under tutorship or curatorship
- Pregnant or breastfeeding woman
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - From admission until the end of hospitalization or death
Blood samples are collected to measure immunity markers, including HLA-DR dosage, at the time of inclusion and once a week thereafter.
Weekly visits for blood collection
Duration - Up to 100 months from hospital admission
Participants are monitored for recurrence or relapse of ventilator-associated pneumonia and other healthcare-associated infections based on immunity marker levels.
Visits coincide with routine clinical care during hospitalization and follow-up
Trial Site Locations
Total: 1 location
1
Centre Hospitalier Intercommunal Aix-Pertuis
Aix-en-Provence, France, 13100
Actively Recruiting
Research Team
L
Laurent LEFEBVRE, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here